Regulatory Affairs Merck Research Laboratories / Clinical Research Merck Research Laboratories / ACS / MPH / PhD / /
Event
FDA Phase / /
Facility
University of North Carolina School / Chapel Hill / /
MedicalCondition
atherothrombotic disease / peripheral arterial disease / intracranial hemorrhage / stroke / cerebrovascular disease / Two Separate Indications Non ST Elevation Acute Coronary Syndrome N / transient ischemic attack / myocardial infarction / coronary arterial disease / /
NaturalFeature
Chapel Hill / /
Organization
Medicine / Harvard Medical School Founding Chairman / TIMI Study Group Brigham and Women's Hospital / Executive Committee for TRA 2°P / Cardiac Intensive Care Unit / Women's Hospital / Department of Medicine / Harvard / Stanford University / University of North Carolina School / Stanford University School / /
Person
Eugene Braunwald / Atherothrombosis Chitkala Kalidas / John Strony Merck / Chitkala Kalidas Merck / Robert A. Harrington / John Strony / Daniel Bloomfield Merck / David Morrow / Samuel A. Levine / David A. Morrow / /
Position
Medicine Vice-Chair / Senior Investigator / TIMI Study Group / Professor / Biostatistics / Chairman / Executive Director / Professor / Principal Investigator / Director / Associate Professor of Medicine / Consultant / Professor Chairman / Study Chair / /
Vorapaxar in Secondary Prevention of Atherothrombosis Chitkala Kalidas, PhD Director, Regulatory Affairs Merck Research Laboratories